Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

May 1, 2021

Conditions

CholangiocarcinomaBiliary Tract CancerTargeted Therapy

Interventions

DRUG

Lenvatinib

Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.

Trial Locations (1)

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT04656249 - Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter